Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
+0.44%
+0.64%
+0.40%
ALT
Altimmune
$4.01
Login to see Altimmune (ALT) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid Chart
$3.78 (+6.08%)
$4.26 (-5.87%)
$5.68 (-29.40%)
$6.88 (-41.72%)
ALT has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
Price under $5
ALT overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Reported a weak earnings
Rating
Rating
Momentum
Momentum
Has been gaining momentum
Activity
Activity
Future
Future
ALT Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
ALT Street view is extremely bullish and have negative views on the near-term outlook
Average key support and resistance price levels.
Login to displayALT Earnings
The TTM reflects 12-month period, providing review of ALT financial performance.
The company financial health is gradually deteriorating, indicating rising risks and weakening fundamentals
Financial Score
What is ALT current stock price?
What are ALT stock strengths?
What risks are associated with ALT stock?
When is ALT next earnings report?
What is ALT market cap and volume?
What is ALT's current Stock IQ?
Should I buy ALT stock right now?
Is ALT a Strong Buy right now?
What does a 'Strong Buy' rating mean for ALT?
What does a 'Strong Sell' rating mean for ALT?
What factors influence ALT's Stock IQ?
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+0.44%
+0.64%
+0.40%
ALT
Altimmune
Current Price
$4.01
Stock Insights
Not Enough Information
Login to unlock Altimmune (ALT) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid
Chart
$3.78 (+6.08%)
$4.26 (-5.87%)
$5.68 (-29.40%)
$6.88 (-41.72%)
ALT Analysts Opinion
ALT Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Reported a weak earnings
Rating
Rating
Momentum
Momentum
Has been gaining momentum
Activity
Activity
Future
Future
ALT Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
ALT Street view is extremely bullish and have negative views on the near-term outlook
ALT has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
Price under $5
Average key support and resistance price levels.
Login to displayALT Earnings
The TTM data reflects the most recent 12-month period, providing overview of ALT financial performance.
ALT Financial Health
The company financial health is gradually deteriorating, indicating rising risks and weakening fundamentals
Financial Score
ALT Latest Analysis
Altimmune Appoints Industry Veteran Christophe Arbet-Engels M.D. PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide. Seasoned clinical leader to oversee Phase 3 development of pemvidutide in MASHDr. Arbet-Engels has led late-stage development regulatory approvals and commercial launches for multiple successful franchises (NASDAQ: ) a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic disease
Mon Sep 29, 2025
Altimmune Appoints Christophe Arbet-Engels To Succeed Scott Harris As Chief Medical Officer . (RTTNews) - Biopharmaceutical company Altimmune Inc. (ALT) announced Monday the appointment of Christophe Arbet-Engels as Chief Medical Officer effective October 1 2025.
Mon Sep 29, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Overview
Trending
Screener
Insights
Top Rated
Momentum
Earnings